|
Oct 16
|
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
|
Oct 16
|
Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth
|
|
Oct 15
|
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
|
Oct 9
|
Lexaria Bioscience Launches Human Study of DehydraTECH-Processed Tirzepatide
|
|
Oct 9
|
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
|
|
Oct 8
|
Lexaria Updates Current GLP-1 Market
|
|
Sep 5
|
Lexaria Releases Strategic Letter from the Outgoing CEO
|
|
Sep 5
|
Lexaria Welcomes Industry Veteran as New CEO
|
|
Jul 23
|
LEXX: GLP-1 Agonist Program Updates
|
|
Jul 16
|
Lexaria Preparing For Strategic Growth
|
|
Jun 18
|
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
|
|
Jan 30
|
Lexaria's Submits Investigational New Drug Application
|
|
Jan 16
|
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
|
|
Jan 11
|
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
|
|
Jan 9
|
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
|
|
Dec 7
|
Lexaria's Investigational New Drug Application Filing Update
|
|
Nov 30
|
LEXX: GLP-1s’ Sweet Opportunity
|
|
Nov 28
|
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
|
|
Sep 29
|
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
|
|
Jul 19
|
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
|